Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for CX Securities Ltd30-06-2017
30-06-2017
Natco to sell generic cancer drug in US
Natco Pharma has received final approval from the US Food and Drug administration (USFDA) for its Abbreviated New Drug Application for the generic version of Vidaza (Azacitidine for Injection). The...27-06-2017
Press Release
RECEIVES FINAL APPROVAL FOR GENERIC AZACITIDINE FOR INJECTION (VIDAZA) for USA market27-06-2017
Natco chief donates shares to Eye Research Foundation
Natco Pharma Vice-Chairman & CEO Rajeev Nannapaneni has donated 1.5 lakh shares valued at 15 crore to the Hyderabad Eye Research Foundation, the research arm of LV Prasad Eye Institute. The...23-06-2017
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for CX Securities Ltd23-06-2017
Natco chairman donates 1.5 lakh shares to Hyderabad Eye Research Foundation
Natco Pharma Vice- Chairman & CEO, Rajeev Nannapaneni has donated 1.5 lakh shares valued at Rs 15 crore to the Hyderabad Eye Research Foundation, the research arm of L V Prasad Eye Institute....22-06-2017
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Rajeev Nannapaneni22-06-2017
Pharma outperformer: Natco looks to new drug approvals to boost growth
Natco Pharma delivered impressive results with a strong Q4, with EBITDA rising 157% YoY, and 22% above analyst estimates. FY17 overall revenues grew an impressive 91% to Rs. 20.65 billion, while net profits expanded 209%. An especially active flu season in the US and increased market share for the company's gTamiflu resulted in strong numbers for the company. The management says that it is now focusing on increasing its investments in India, and other international markets given improving regulatory standards. Regulatory standards being strengthened in Indian markets, with inspections now mandatory for every product approval, Natco believes, will reduce competition from cheap but low-quality medications, improving opportunity here. In the case of US, the company is pushing for a significant scale-up, cashing in the first wave of limited competition products (gTamiflu, gNuvugil, gEntocort, gDoxil), while also planning 3 new launches for FY18 (gVidaza, gFosrenol, gTamiflu oral suspension). A strong US pipeline is expected to help Natco weather intensifying competition in the US market better than other pharma companies. In the short term, the GST is set to have an impact on the June quarter, but Natco says it expects sales to bounce back in July as the business adjusts. The company's new Vizag facility is expected to open in July 2017. Axis Direct and other analysts have been bullish on the firm despite some short-term GST related upheaval. The share price of the company hit a new year high today - it has gained over 80% so far in 2017.09-06-2017
Natco Pharma hits new high; up 80% in 2017
The stock hit a new high of Rs 1,054, up 3%, extending its 15% gain in past eight trading sessions.09-06-2017